Decentralized Clinical Trials: 2026 Guide to DHTs & Design

Clinical research has traditionally been a place of boundaries. It happened within the walls of a specific hospital or research center, requiring patients to travel, often long distances, just to participate. But what if we could bring the trial to the patient? That’s the revolutionary idea behind decentralized clinical trials, a model where some or all trial activities occur away from a traditional research site. This approach is reshaping how we develop new medicines and therapies by putting the participant first.

This guide breaks down everything you need to know about this modern approach, from the technology that powers it to the roles and responsibilities that make it work.

What Are Decentralized Clinical Trials?

In a decentralized clinical trial (DCT), the study comes to the participant rather than the other way around. Instead of participants constantly traveling to a clinic, trial activities are conducted through local healthcare facilities, in home visits, or telemedicine.

These trials can be fully remote or a hybrid mix, where certain appointments (like a complex MRI) still happen at a physical site while routine follow ups are done virtually. The goal is to make participation more convenient, which helps improve patient recruitment, retention, and participant diversity. Studies show this model can even lower trial costs in some cases.

More Than Digitization: A Digital Transformation of Research

It is important to distinguish between digitization and digital transformation. Digitization is simply using a digital tool to do the same old process, like using a PDF instead of a paper form. Digital transformation, however, is about fundamentally rethinking and redesigning the entire workflow. DCTs represent a true digital transformation of research. They are not just about adding an app, but about building a new, more flexible, and participant focused research model from the ground up.

The Technology Powering the Shift: Digital Health Technologies (DHTs)

The engine that drives decentralized clinical trials is a set of tools known as Digital Health Technologies, or DHTs. These are the devices and software that collect health data directly from people wherever they are.

Think about things like:

• Wearable sensors (like a smartwatch tracking heart rate)
• Smartphone apps for reporting symptoms
• Digital blood pressure cuffs
• Software platforms for video calls with doctors

DHTs allow for continuous, real world data capture that was impossible with only periodic clinic visits. Their use is growing rapidly, with the number of clinical trials incorporating digital health tech more than doubling between 2019 and 2021. These tools are the technological backbone of modern research.

The Opportunity: Making Research More Inclusive and Efficient

Digital health technologies unlock massive opportunities. A huge challenge in research is access. For example, fewer than 5% of cancer patients enroll in clinical trials, partly because they cannot travel to distant research sites. DHTs allow these patients to contribute data from home, potentially opening up research to the other 95%.

By removing geographic barriers, decentralized clinical trials can dramatically improve the diversity of participants, ensuring new treatments are tested on a population that better reflects the real world. The benefits are so clear that after the pandemic forced a rapid shift to remote methods, one survey found that 83% of research organizations planned to continue using them.

Community Health and the Decentralized Approach

A key benefit of the decentralized model is its ability to integrate with community healthcare. Instead of relying on a few large academic centers, DCTs can partner with local clinics, labs, and even retail pharmacies to conduct trial activities. This not only makes participation more convenient but also builds trust by meeting patients in familiar settings. Engaging community providers helps reduce cultural and language barriers, making research more accessible and representative of the general population.

Designing and Implementing Modern Clinical Research

Shifting to a decentralized model requires careful planning and an approach based on risk. The COVID 19 pandemic was a major turning point. In early 2020, the FDA issued emergency guidance urging trial sponsors to adopt remote methods to keep studies going.

How to Design a Decentralized Clinical Trial

When designing a study, the first decision is whether it will be fully remote or a hybrid model. A hybrid design might have an initial in person visit for a baseline scan, with all subsequent follow ups conducted virtually.

Key design principles include:

• Flexibility for Participants: The protocol is built to minimize travel and inconvenience. However, designers must also account for potential data variability that comes with this flexibility (for instance, measurements taken at different times of day).
• Location Suitability Assessment: A critical step is evaluating the feasibility of different locations, whether it’s a participant’s home, a local clinic, or a mobile research unit. This assessment ensures that chosen locations have the necessary resources and technology to conduct trial activities safely and effectively.
• Leveraging Local Resources: The trial can partner with local clinics, labs, or mobile research units to handle procedures near the participant. This not only adds convenience but also helps build trust.
• Suitability of the Intervention: Not every drug is a good fit for home use. Common interventions in DCTs include oral medications, digital therapeutics (DTx), and diagnostic tests. FDA guidance says investigators must evaluate if a product can be safely shipped, administered, and monitored remotely.

Special Considerations for Medical Devices

Investigational medical devices require unique planning in a DCT. The suitability of a device for remote use depends on its intended purpose, instructions, and risk level. Devices designed for home use that do not pose a significant risk may be appropriate for participants to use without direct supervision. However, devices that are not intended for self use or carry higher risks should only be handled by qualified personnel under the investigator’s oversight. The selection of any device, from a connected sensor to a complex diagnostic tool, must prioritize ease of use for the participant and ensure data can be validated.

Remote Clinical Visit Planning

A core part of DCT design is planning remote visits. This involves more than just scheduling a video call. A comprehensive plan coordinates various logistics, such as deploying mobile nurses for in home blood draws, shipping supplies to participants, and scheduling appointments with local labs or imaging centers. The goal is to create a seamless experience where participants know exactly what to expect.

Consideration for Special Populations

DCTs offer significant advantages for special populations who often face the greatest barriers to participation. For pediatric trials, this means less time away from school and reduced family disruption. For older adults, it eliminates the challenges of transportation and mobility. For patients with rare diseases, it allows them to participate from anywhere, vastly expanding the potential recruitment pool.

Roles, Responsibilities, and Quality Oversight in DCTs

While the location of trial activities may change, the fundamental responsibilities for safety and data quality do not. Regulatory agencies have been clear that using decentralized methods does not reduce a sponsor’s or investigator’s obligations.

Sponsor and Investigator Responsibilities

The sponsor is ultimately responsible for the study’s design, safety oversight, data quality, and compliance. In a decentralized trial, this expands to include new duties like:

• Selecting appropriate and validated digital health technologies.
• Implementing a robust risk assessment and mitigation plan.
• Ensuring all staff, including remote personnel like home health nurses, receive thorough training.
• Managing and overseeing various third party vendors.
• Implementing a robust data management plan that accounts for all remote data sources.

The Principal Investigator (PI) retains the same core duties, including protecting participant safety and ensuring data quality. In a decentralized setting, the PI must provide adequate supervision for any remote personnel and review incoming digital data in real time.

IRB Oversight and Third Party Collaborators

Institutional Review Boards (IRBs) play a crucial role in DCTs, and their oversight requirements are the same as for traditional trials. Any third party collaborator, such as a home health agency or a technology platform provider, that is engaged in research activities requires IRB oversight. The IRB must review the qualifications of third party personnel and ensure that contracts and agreements clearly define responsibilities, especially regarding participant privacy and data security. The PI remains responsible for the conduct of these third parties throughout the trial.

Navigating Global Regulatory Guidance

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have published guidance on DCTs. Both agencies prioritize participant safety and data integrity as core pillars for assessing any decentralized element. However, subtle differences exist.

For instance, the FDA permits fully decentralized trial models, while the EMA currently favors hybrid models that retain some site visit options. Their approaches to remote informed consent also vary, with the EMA’s position being less uniform due to differences among member states. Sponsors must carefully review the specific guidance for every region where their trial will operate to ensure full compliance.

FDA Oversight and Inspections

The FDA’s expectations for Good Clinical Practice (GCP) are the same for decentralized trials as for traditional ones. During an inspection, investigators must be able to provide access to all trial related records, even if they are stored electronically across different systems. This means having a physical location where an inspector can review these records is recommended. Sponsors should maintain clear records of all service providers, their roles, and a detailed data management plan that outlines the flow of data from all remote sources.

The Core Components and Technology of a DCT

Several key activities and tools form the foundation of most decentralized clinical trials. These components work together to create a seamless remote experience.

Remote Visits and Telehealth

In a decentralized trial, many traditional activities are done remotely. A follow up visit might be a secure video call with a study coordinator. This flexibility has been linked to higher participant satisfaction and better participant retention. However, using telehealth across state lines introduces legal complexities. Investigators must comply with the licensing laws of the state where the participant is located.

Remote Informed Consent (eConsent)

Remote informed consent, also known as eConsent, is the process of using digital platforms for participants to join a study. Instead of signing paper forms, participants can review study information on a tablet or smartphone, watch informational videos, and sign electronically.

Selecting and Validating a Unified eClinical Platform

Choosing the right software platform is critical. An all in one platform that combines eConsent, ePRO (electronic patient reported outcomes), telehealth, and an integrated EDC for data capture simplifies workflows. Key considerations include:

• Regulatory Compliance: The system must be 21 CFR Part 11 compliant and adhere to privacy laws like HIPAA. The FDA expects electronic systems used in trials to meet these standards.
• Data Reliability and Integrity: The platform must ensure the data is accurate, complete, and trustworthy. A robust system for data validation and query management is essential.
• Usability: The software must be user friendly for both participants and site staff. A poor user experience can lead to high dropout rates.
• Vendor Validation: Sponsors should ensure the software vendor has undergone proper validation and security reviews to protect sensitive patient information.

An integrated eClinical platform is essential for running smooth and compliant studies. To see how a unified system can manage all aspects of a modern trial, explore the Curebase platform.

Investigational Product Logistics

Managing the study drug or device requires special planning. Sponsors must develop clear procedures for packaging, shipping, and tracking investigational products sent directly to participants. Key factors include temperature stability, ensuring the chain of custody, and handling the return of unused products.

The Future of Clinical Research is Here (And What’s Next)

Decentralized clinical trials represent a fundamental shift towards a more accessible, efficient, and patient focused future for medical research. The future holds even greater opportunity. We can expect to see deeper integration with electronic health records (EHRs), the use of artificial intelligence to analyze real world data in real time, and hyper personalized trial experiences that adapt to individual participant needs. By leveraging technology to bring studies directly to participants, we can accelerate the development of new treatments.

Ready to design a clinical trial that meets patients where they are? Schedule a demo to see how Curebase can help you launch your next study.

Frequently Asked Questions about Decentralized Clinical Trials

What is the difference between a hybrid and a fully decentralized clinical trial?

A fully decentralized clinical trial has no traditional site, and all activities occur remotely (at home, local clinics, etc.). A hybrid trial combines remote activities with some required in person visits at a central research site.

Are decentralized clinical trials safe for participants?

Yes. Safety is the top priority. Protocols for decentralized clinical trials include robust plans for remote monitoring, handling adverse events, and emergency procedures. Continuous data collection can help investigators spot potential issues even earlier than in traditional trials.

How do DCTs improve patient diversity?

By removing the need for frequent travel, decentralized clinical trials open up participation to people who live far away, have mobility issues, or have work and family commitments. This broadens the geographic and demographic reach of a study.

What is eConsent?

eConsent, or electronic informed consent, is a process that uses digital tools to inform a participant about a study and obtain their consent to join. It often includes multimedia elements like videos to improve understanding and allows for an electronic signature.

Can any clinical trial be decentralized?

Not every trial is a good fit. Suitability depends on the investigational product, the complexity of procedures, and the patient population. However, many elements of decentralization can be incorporated into almost any trial to reduce patient burden.